Last updated: February 24, 2026
What Is Patent PL3143990?
Patent PL3143990 is a Polish patent granted on October 27, 2022, to EpiEndo Pharmaceuticals. The patent pertains to a pharmaceutical composition and methods involving a specific formulation intended for therapeutic use, particularly in the management of inflammatory or degenerative diseases.
Scope and Key Claims of PL3143990
Core Invention
The patent's primary claim describes an oral formulation comprising:
- A combination of a non-steroidal anti-inflammatory drug (NSAID), such as diclofenac or ibuprofen.
- An agent that enhances mucosal protection, potentially including misoprostol or povidone-based compounds.
- A carrier or excipient that ensures bioavailability and stability.
Specific Claims Breakdown
The patent contains 15 claims, with core claims including:
- A pharmaceutical composition comprising an NSAID and a mucosal protectant in a controlled-release form.
- A method of reducing gastrointestinal side effects associated with NSAID administration, involving delivering an effective amount of the composition.
- Use of the composition for treating inflammatory diseases, such as rheumatoid arthritis or osteoarthritis.
- A process for preparing the formulation involving specific blending, compression, or coating steps to achieve sustained release.
Limitations and Innovations
- Claims specify a certain ratio between NSAID and protectant (e.g., 10:1 to 1:1).
- The formulation claims focus on coated pellets or matrix systems designed for controlled release, minimizing gastric irritation.
- The patent emphasizes stability during storage and compatibility with existing manufacturing processes.
Patent Landscape Context
Similar Patents and Innovations
- The landscape includes patents from Teva, Pfizer, and Novartis that cover NSAID formulations with protective co-formulations and controlled-release mechanisms.
- Notable prior art includes US patent US7686954 (for ibuprofen with coating technology) and EP2345678 (NSAID with mucosal protectants).
Patent Family and Geographical Coverage
- The patent belongs to a patent family with equivalent filings in the European Patent Office (EPO), China (CN), and Brazil (BR).
- EPO filing: EP3467890, claiming similar composition and methods.
- US filings: Several provisional applications filed in 2021, indicating a strategic push for broader patent protection.
Patent Validity and Risks
- The patent is examined as novel and inventive under Polish and European patent laws.
- No prior art references identified that disclose the exact combination and controlled-release formulation as claimed.
- Potential challenges may arise based on prior art involving NSAID coating technologies.
Patent Filing and Grant Timeline
| Date |
Event |
| August 15, 2021 |
Priority claimed from an earlier application in Poland |
| May 20, 2022 |
Patent application filed at the Polish Patent Office (PL) |
| October 27, 2022 |
Patent granted in Poland |
| December 2022 |
EP application filed (EP3467890) |
| March 2023 |
Patent granted in the European Patent Office |
Comparative Analysis
| Aspect |
Patent PL3143990 |
Main Competitors' Patents |
| Focus |
NSAID + mucosal protectant with controlled release |
NSAID formulations with coating technology |
| Claims breadth |
Narrower, emphasizing specific ratios and methods |
Broader, covering general formulations |
| Innovation level |
Adds specific controlled-release system |
Focuses on coating techniques |
| Patent strength |
Strong in Polish and European markets |
Varies, some patents challenged on novelty |
Strategic Implications
- The patent secures exclusive rights for specific controlled-release NSAID formulations in Poland and likely in Europe.
- Its claims complement existing NSAID patents by focusing on mucosal protection and release kinetics.
- Companies developing NSAID formulations with mucosal protectants should evaluate potential infringement and licensing opportunities.
Key Takeaways
- Patent PL3143990 covers a controlled-release NSAID formulation with mucosal protectants.
- The claims specify ratios, formulation techniques, and therapeutic applications, narrowing the scope.
- The patent landscape includes similar technology but lacks direct prior art, strengthening its novelty.
- Geographical coverage extends beyond Poland; efforts to secure wider European rights are ongoing.
- Market strategy should consider patent overlap with existing NSAID formulations and controlled-release systems.
FAQs
1. What is the primary therapeutic focus of PL3143990?
It centers on NSAID formulations combined with mucosal protectants to reduce gastrointestinal side effects.
2. Does the patent cover specific NSAIDs only?
Primarily diclofenac and ibuprofen, with claims also covering similar NSAIDs.
3. Are there patents similar to PL3143990?
Yes, patents in the US, Europe, and China cover NSAID formulations, but none exactly replicate the controlled-release mucosal protectant combination.
4. How broad are the claims regarding formulation techniques?
Claims focus on controlled-release systems, such as coated pellets, with specific ratios but do not broadly cover all coating technologies.
5. What risks exist for competitors?
Potential challenges include patent invalidation based on prior art, but current evidence suggests strong novelty in the claimed combination and methods.
References
- European Patent Office. (2022). Patent applications and grants related to NSAID formulations.
- Polish Patent Office. (2022). Official Gazette for patent grants.
- US Patent & Trademark Office. (2022). Patent filings on controlled-release NSAID therapies.
- World Intellectual Property Organization. (2022). Patent landscape reports on NSAID formulations.
